Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Robert J. Motzer, Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B Apolo, Maria T. Bourlon, Amishi Yogesh Shah, Camillo Porta, Cristina Suárez, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Fatima A. Rangwala, Margarita Askelson, Julie Panzica, Viktor Fedorov, Toni K. Choueiri
Institutions: Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Queen Mary University of London, The Royal Free Hospital, Cancer Research UK, Barts Cancer Institute, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, The University of Texas MD Anderson Cancer Center, University of Bari Aldo Moro, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Latin American Cooperative Oncology Group (LACOG), Instituto Oncológico de Córdoba, Westmead Hospital, Macquarie University, University of Colorado Anschutz, University of Colorado Denver, Niigata University, Klinikum Stuttgart, Exelixis (United States), Bristol-Myers Squibb (United States), Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407678366